Approxima S.r.l. is developing a percutaneous tricuspid valve repair system based on a ventricular reshaping approach, intended to treat tricuspid valve regurgitation by addressing right ventricle dilation and annulus remodeling. The company targets patients with tricuspid regurgitation, a condition affecting over 13 million people worldwide, most of whom are considered too high-risk for open-heart surgery.
Subscribe to see Approxima S.r.l.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Approxima S.r.l. is a medical devices (cardiovascular) company headquartered in Italy. Its most recent funding round raised $7.6M in February 2025.
As of 16 November 2026. Source: Xcout Intel.
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $7.6M | 3 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Approxima S.r.l.? Suggest a correction · Work at Approxima S.r.l.? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.